Comply with good pharmacovigilance practice and prepare for an inspection.
Similar Posts
Class 2 Medicines Recall: Zaditen 0.25 mg/ml, eye drops, solution, Laboratoires Théa EL(25)A/34
Laboratoires Théa trading as Thea Pharmaceuticals Limited have notified the MHRA of an out of specification event related to environmental monitoring during manufacturing, which may increase the risk of microbial contamination of the medicinal product.
Field Safety Notices: 8 – 12 December 2025
List of Field Safety Notices from 8-12 December 2025
Brensocatib licensed as the first medicine specifically designed to treat non-cystic fibrosis bronchiectasis in patients 12 years and older
As with any medicine, the MHRA will keep the safety and effectiveness of brensocatib under close review.
Guidance: CLOSED AI Airlock Phase 2 application
The call for applications for phase 2 of the AI Airlock is now closed.
The new Innovative Licensing and Access Pathway welcomes first investigational products
Developers work with the NHS, the medicines regulator and the UK health technology assessment bodies from the early stages of clinical development, as part of the Innovative Licensing and Access Pathway.
MHRA welcomes Professor Jonathan Benger CBE as new CEO of NICE
Professor Benger’s leadership comes at a pivotal time as the MHRA and NICE deepen collaboration